Abstract
The yellow fever virus (YFV) recently reemerged in the large outbreaks in Africa and Brazil, and the first imported patients into Asia have recalled the concerns of YFV evolution. Here we show phylogenomics of YFV with serial clinical samples of the 2016 YFV infections. Phylogenetics exhibited that the 2016 strains were close to Angola 1971 strains and only three amino acid changes presented new to other lineages. Deep sequencing of viral genomes discovered 101 intrahost single nucleotide variations (iSNVs) and 234 single nucleotide polymorphisms (SNPs). Analysis of iSNV distribution and mutated allele frequency revealed that the coding regions were under purifying selection. Comparison of the evolutionary rates estimated by iSNV and SNP showed that the intrahost rate was ~2.25 times higher than the epidemic rate, and both rates were higher than the long-term YFV substitution rate, as expected. In addition, the result also hinted that short viremia duration of YFV might further hinder the evolution of YFV.
Author summary
The first importation of infections into China in 2016 and the following outbreaks in Africa and Brazil of yellow fever virus (YFV) have raised again the concerns of the potential viral spread into new territories. In this study, we aimed to know the evolution dynamics of YFV by using intrahost phylogenomics and to assess the risk of virus epidemics. Through deep sequencing of consecutive samples from 12 patients, we identified hundreds of genomic variations (iSNVs and SNPs), and noticed the nearly linear accumulation of variations within individuals. The estimated evolutionary rate within host is much higher than the epidemic evolutionary rate. In comparison with Dengue virus (DENV) and Zika virus (ZIKV), which share similar host vectors (Aedes spp.), life cycles, mutation rates and replication strategies to YFV, the lower epidemic evolutionary rate of YFV might have been hindered by the shorter viremia duration, which decreased the accumulated variations to get into the transmission cycle.
Introduction
Yellow fever is a notorious mosquito-borne viral disease emerged during the 15th-19th centuries in the Americas, Africa and Europe, causing severe hemorrhagic fever and liver injury with high mortality rates. Although control of mosquitoes and the use of the live-attenuated yellow fever virus (YFV)-17D vaccine strain have effectively prevented and controlled the epidemics, YFV is estimated to cause approximately 30,000 deaths out of 200,000 infections annually worldwide, mostly in Africa (https://www.cdc.gov, last accessed 10th April, 2018). The etiological agent of the disease, YFV, is a single-stranded, positive-sense RNA virus with a ~11 kb genome in length. The virus is frequently transmitted between nonhuman primates and mosquitoes in African and American jungles, known as the sylvatic cycle [1]. Occasionally, YFV can escape from the sylvatic cycle to infect humans, with subsequent transmission between mosquitoes and humans, forming the urban cycle. Historically, YFV was believed to have originated from Central or East Africa, and transmitted to America during the slave trade [2, 3]. Currently, YFV in Africa and America are classified into seven genotypes, with two in South America, two in West Africa, and three in East and Central Africa [2, 4, 5].
In January 2016, the Ministry of Health of Angola notified the World Health Organization (WHO) of a yellow fever disease outbreak: as of October 28th, 4,347 suspected cases, including 377 deaths, were reported from all 18 provinces of Angola. Outbreaks were also reported simultaneously from the Democratic Republic of Congo and Uganda [6]. In February 2018, 464 confirmed human cases of yellow fever have also been reported in Brazil, with 154 deaths (http://www.who.int, last accessed 10th April, 2018). Meanwhile, epizootics have expanded to areas previously not considered at risk for yellow fever (http://www.who.int/csr/don/27-february-2018-yellow-fever-brazil/en/, last accessed on 10th April, 2018). All these recalled the concerns of the evolution of YFV. During the Angolan outbreak, YFV infections were detected in Chinese workers returning to China from Angola [7–9], marking the first time YFV infections were documented in Asia. By using the consecutive samples from those imported YFV patients, we unraveled the intrahost and epidemic evolutionary dynamics of YFV.
Results
Deep sequencing of YFV genomes from clinical samples
We collected samples from twelve out of thirteen YFV patients in China, sequenced the viral genomes, and performed analyses on phylogenetics, sequence comparison, and intra-host dynamics. Of the 12 patients, two had severe disease, in which one survived (YF-BJ3) and one died (YF-BJ1), and the remaining patients displayed mild symptoms (Table 1). We tested blood samples of these 12 patients from the first day of admittance to the hospital by real-time reverse transcription PCR (RT-PCR), and four patients (YF-BJ1, YF-BJ2, YF-BJ3, and YF-BJ5) were positive. YFV RNA fragments could be detected in serum until 9, 12, 10 and 6 days, respectively, after the onset of symptoms (Table 1, and Fig 1). Urine samples from all patients were also tested by real-time RT-PCR and all were YFV-positive. Higher viral RNA loads were observed in the urine compared to the blood samples, except for those from the non-survivor (Table 1). The virus persisted in urine samples for at least 15 days after the onset of symptoms in survivors. Specifically, the urine sample from patient YF-BJ3 was still PCR-positive when tested 32 days after the onset of symptoms (Table 1 and Fig 1). We then sequenced all available YFV-positive samples by using total RNA sequencing, amplicon sequencing and/or Sanger sequencing (Table 1 and S1 Table). In total, nearly complete virus genomes (>10,222 bp) from 9 patients, and deep-sequenced genome datasets (average sequence depth 34,978x) from 3 patients covering 12 time points were obtained (Table 1).
Table 1. Patient information, viral loads and genome sequencing in urine samples.
Patient ID | Group | Outcome | Days after onset | Blood virus (Ct)* | Urine virus (Ct)* | Sequencing Method† | # Total Reads | # Mapped Reads | Sequencing Depth (x1000) | Genome Coverage (bp) |
---|---|---|---|---|---|---|---|---|---|---|
YF-BJ1 | Severe | Death | 7 | 31 | 35.00 | AS | 1,695,368 | 1,509,993 | 30.98 | 10,732 |
8 | 32 | 33.50 | AS | 1,661,085 | 953,063 | 19.67 | 10,650 | |||
9 | 30 | 34.42 | AS | 3,303,973 | 1,952,626 | 35.68 | 10,725 | |||
YF-BJ3 | Severe | Discharged | 8 | 27.6 | 25.60 | AS | 1,451,105 | 1,354,090 | 27.59 | 10,650 |
10 | 27.9 | 25.32 | AS | 1,941,400 | 2,369,835 | 18.97 | 10,393 | |||
14 | - | 32.85 | AS | 4,034,937 | 2,896,728 | 55.05 | 10,405 | |||
17 | - | 31.66 | AS | 1,998,163 | 1,861,631 | 36.67 | 10,397 | |||
20 | - | 34.00 | AS | 1,920,032 | 1,416,518 | 28.89 | 10,393 | |||
32 | - | 39.83 | AS | 1,424,735 | 1,014,331 | 21.80 | 10,650 | |||
YF-BJ5 | Mild | Discharged | 6 | 23.84 | 23.77 | AS | 2,001,845 | 1,866,672 | 37.82 | 9,918 |
10 | - | 35.42 | AS | 1,684,026 | 1,014,398 | 18.54 | 10,674 | |||
14 | - | 34.23 | AS | 2,090,128 | 840,862 | 16.56 | 10,394 | |||
YF-BJ2 | Mild | Discharged | 16 | - | 30.95 | AS | 1,924,145 | 1,467,048 | 30.21 | 10,398 |
YF-BJ4 | Mild | Discharged | 19 | - | 35.86 | TS | 56,728,408 | 873 | 0.02 | 10,393 |
YF-FZ1§ | Mild | Discharged | 6 | - | - | TS | 77,238,978 | 129 | 0.00 | 1,012 |
YF-FZ2¶ | Mild | Discharged | 16 | - | 39.37 | TS | 58,570,126 | 195 | 0.00 | 10,243 |
YF-FZ3§ | Mild | Discharged | 14 | - | 39.40 | TS | 50,462,246 | 68 | 0.00 | 839 |
YF-FZ4¶ | Mild | Discharged | 7 | - | - | TS | - | - | - | 10,222 |
YF-FZ5§ | Mild | Discharged | 6 | - | - | TS | 56,605,654 | 68 | 0.00 | 2,795 |
YF-FZ6¶ | Mild | Discharged | 20 | - | 32.44 | TS | 51,627,058 | 4,722 | 0.11 | 10,838 |
YF-FZ7¶ | Mild | Discharged | 15 | - | 33.96 | TS | 64,345,650 | 3,945 | 0.09 | 10,311 |
* “-”, Negative results (Ct value >45).
† AS, amplicon sequencing; TS, total RNA sequencing.
¶ Genome sequence assembled with Sanger sequencing data.
§ Genome sequence failed to assemble.
Phylogenetics and sequence comparison of YFV genome
We performed phylogenetic analysis of the coding region of YFVs (S2 Table), and found that YFV sequences from the returning workers in 2016 outbreak closely clustered with the 1971 Angola strains (Fig 2A). Of note, the vaccine strain YF-17D and its derivatives are located far from the Angola strains on the phylogenetic tree. A closer inspection of the Angola strains shows that the viruses in the 2016 outbreak are likely from a single origin and genome sequences from both severely ill patients are closely clustered (Fig 2B). There are 188 nucleotide substitutions between the 1971 and 2016 consensus sequences and 6 of them are nonsynonymous substitutions. Comparison of the YFV polypeptides shows that only three amino acid changes that appear to be specific to the Angola 2016 strains (Fig 2C). Two are in the capsid protein and one in NS5, the RNA-dependent RNA polymerase. The above data are consistent with previous studies using partial or whole genomes showing that YFV exhibits a slow evolutionary rate [2, 4, 10].
Intrahost genomic variations
For the deep-sequenced samples, we identified the iSNVs by using methods in a previous study for Ebola virus [11]. The mean sequencing depth of genomic regions is between 16,558x and 37,822x (Fig 3A), and a total of 101 iSNV sites were discovered, including 69 in the coding region and 32 in non-coding regions. In each iSNV sites, we only found two types of nucleotides. Taken that sequencing errors are generated randomly and may result in multi-nucleotide heterogeneity in a single site, it is unlikely those iSNVs were the results of sequencing bias. Fewer iSNVs appeared in the 1st and 2nd codon positions than the 3rd codon position (Fig 3B) and fewer non-synonymous than synonymous iSNVs (Fig 3C), implying that the coding region is generally under purifying selection. We plotted the distributions of all mutated allele frequencies of the iSNVs (Fig 3D and 3E). The mean mutated allele frequency of non-coding iSNVs was at 0.18, while that of synonymous and non-synonymous iSNVs was 0.12 and 0.09, respectively (Fig 3D). Among them, non-synonymous iSNV is significantly lower than that in non-coding regions (P = 0.02). The distribution of non-coding iSNVs is close to the expected neutrality, whereas curves of synonymous and nonsynonymous iSNVs have higher portions of iSNVs in the area of low mutated allele frequencies (Fig 3E). This further supports the notion that the coding region was under purifying selection. Additionally, we discovered two variant types at the 3’ untranslated region (UTR), one with 5 concurrent iSNVs (G10360A, U10365G, C10367U, G10373A, and U10398C) and the other having an additional iSNV (A10425G) (Fig 3F). Phasing analysis reveals that these iSNVs tend to be concurrent in the same reads (S3 Table and S1 Fig). Predicted RNA structure shows that these substitutions are likely to affect the structure of the 3’ UTR (Fig 3F and S2 Fig), and probably influence viral replication in hosts [12–14].
Intrahost evolutionary dynamics
Subsequently, we placed all of the polymorphic sites (SNPs and iSNVs) along viral genome (Fig 4A). SNPs and iSNVs described the viral difference in two levels of between and within the host, respectively. Within 65 days (from the onset of the first patient to the sample of the last patient in this study) we observed a total of 234 SNPs in 148 sites in 18 samples, including 102 synonymous and 117 nonsynonymous SNPs. A total of 138 SNPs that appear only once are scattered along the viral genome. In particular, the SNPs of 5 sites (T900A, A2352C, C3918A, G6463A, and A7320G) could be used to characterize the 2016 YFVs. All five SNPs were detected in seven patients, four SNPs (without A7320G) were detected in one patient (YF-BJ5), and only one patient (YF-BJ3) does not possess any of the above SNPs (Fig 4A). Of note, YF-BJ1 is likely a co-infection with more than one YFV variant, as the virus genome on day 7 does not contain any of the five SNPs, whereas all five SNPs became dominant on day 8 (Fig 4A). Of the five SNPs, only G6463A is nonsynonymous, resulting in an amino acid substitution from Val to Ile in NS4A.
We then compared the accumulation of polymorphic sites within patients over time (Fig 4B). Each sample was set to days after onset of the symptoms of the patients it belongs to. Linear regressions revealed that iSNVs and SNPs accumulated from the day of onset of symptoms at a rate of 0.72 and 0.32 variations/day, respectively. The accumulation rate of iSNV may reflect the intrahost evolution. Intriguingly, the YFV evolutionary rate within humans is roughly 2.48 x10-2 variations/site/year (0.72 variations/day = 0.72 x 365 / 10591 variations/site/year = 2.48 x10-2 variations/site/year) in our study. Of those synonymous variations, the intrahost evolutionary rate estimated by iSNV was 0.7 x10-2 variations/site/year; whereas the rate of nonsynonymous variations was 1.2 x10-2 variations/site/year. Compared to the rates estimated by SNP within these samples, the intrahost evolutionary rate of non-synonymous sites (by iSNV) is higher, while the rate of synonymous sites is slightly higher than the SNP rate.
Discussion
The evolution of YFV is a basic question to unfold to predict the risk of the pathogens. Phylogenetic analysis suggests that the 2016 outbreak is likely the spillover of YFV viruses in Angola. The high identity between the 2016 strain and the vaccine strain YF-17D would explain the effectiveness of the current vaccines [15]. Although there is a diversity of yellow fever virus genotypes, all genotypes are indistinguishable in serological assays. There is not any evidence that the Angola outbreak was due to immune escape and it is accepted among public health professionals that low vaccine coverage in the area prior to the outbreak was the driving factor and the resulting aggressive mass vaccination campaign was vital for containing and eliminating the outbreak. However, it should be noted that the Angola lineage is clearly diversified from the 17D-lineage (Fig 2A). Moreover, we did notice 6 patients who had been vaccinated before [16], but the limited clinical and epidemiological data cannot tell the immune escape. Future immune escape from current YFV vaccines cannot be fully ruled out, although YFVs evolve very slowly [17]. A novel vaccine based on a Central/East African YFV isolate would be necessary as a complement vaccine to prepare against future outbreaks. Owing to the slow evolutionary rate and the past experience of using YF-17D, the novel vaccine is likely to work for another decades.
Virus evolution experienced mutation, selection within and between hosts, genetic drift, and transmission, and finally formed the genetic variants (lineages) over long-term evolutionary timescales [18]. Deep sequencing of viral genomes can provide novel insights into viral evolutionary dynamics [19, 20]. In this intra-host phylogenomic analysis, we depicted the evolutionary process of YFV from intra-host to epidemic substitutions, which were reflected by iSNV to SNP, respectively. Other than using the metric for long-term evolutionary rate, we applied the substitution/site/day to measure the intrahost evolutionary rate, which appeared more appropriate in outbreak or epidemic scenarios. Short-term rates may provide better insight into the intrahost YFV evolutionary trends (e.g., iSNV dynamics over time) relative to clinical symptomology, severity, and/or co-morbidities. However, further in vitro or in vivo studies would be needed. The estimated evolutionary rates clearly showed that the intrahost evolutionary rate is ~2.25 times higher than that of the epidemic evolutionary rate, and both are much higher (59 times and 26 times) than the substitution rate of YFV along longer evolutionary timescale [10]. The higher rate estimated by iSNV reflected purifying selection occurred, when intrahost variations were spreading out. The rates estimated by synonymous iSNV and SNP, respectively, were similar, implying that the synonymous variations were under similar evolutionary constraints during transmission. Meanwhile, only a few of the nonsynonymous variations were spread out in different individuals, and only G6463A (Val to Ile in NS4A) were detected in multiple samples.
Compard to Dengue virus (DENV) and Zika virus (ZIKV), YFV shares similar host vectors (Aedes spp.) and life cycles [21, 22], and has similar mutation rates and replication strategies [10, 23, 24]. However, the long-term substitution rates of DENV (0.77–0.99 x10-3 substitutions/site/year) and ZIKA (0.98–1.06 x10-3 substitutions/site/year) are higher than that of YFV [23, 25, 26]. Previous studies have posed that additional constrained selection forces are probably existed [10, 27]. Based on our results, we noticed the nearly linear accumulation of variations within individuals. Since the transmission of YFV variants needs mosquitoes as vector, the window (viremia duration) that mosquitoes could use is essential, as only the variations within this period could be brought into the transmission cycle. A wider window size would possibly allow more non-synonymous variations into the transmission cycle (Cristina Domingo, EID, 2018). Given that YFV, DENV and ZIKV have ~3, 3–7, and 4–7 days of viremia, respectively, after symptom onset (S4 Table), it hinted that the shorter viremia duration in YFV infections might result in the lower evolutionary rate than that of DENV or ZIKV. Most Flaviviruses are vector-borne viruses and the evolutionary rates in mammals and arthropods are different. The intrahost analysis of virus could show the short-term evolution dynamics, especially from serial samples, and this would be a helpful complement to the long-term evolution of Flaviviruses.
In addition, deep sequencing and viral genomics have provided new insights into viral evolutionary dynamics, especially in a continuous mode. Our findings strongly suggest that the urine samples should be considered for the clinical diagnosis, genomic surveillance, and large-scale screening of YFV infections. Further investigations are also encouraged to characterize the factors that maintain viremia in vector-borne diseases.
Methods
Ethics statement
The study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of Beijing Ditan Hospital (DSRB 2008/00293 and DSRB 2013/00209). Clinical samples and information were obtained after written informed consents from all participants. All human subjects were adult, and if not, whether a parent or guardian of any child participant provided informed consent on their behalf.
Patients and data collection
Twelve YFV patients returning from Angola were recruited (Table 1). We sampled urine and blood sample of these patients from routine examination and collected their clinical data.
YFV diagnosis and virus detection
YFV infection was diagnosed according to the WHO guidelines (http://www.who.int/csr/disease/yellowfev/case-definition/en/, last accessed 10th April, 2018), including clinical symptoms (fever, headache, jaundice, etc.) and laboratory detection of virus by using real-time RT PCR. The serum and urine samples were collected and stored at -80 oC for further analyses, including real-time RT-PCR, PCR sequencing and RNA sequencing.
Next generation sequencing
RNA from both serum and urine samples were deployed to two approaches of deep sequencing. Approach I: Total RNA sequencing. RNA was purified by Trizol (Thermo Scientific) for each sample, and then total RNA libraries were constructed with 500bps insertion size using the NEBNext UltraTM RNA Library Prep Kit (NEB, MA, USA), and then sequenced by Illumina Hi-seq platform, and generated 2 × 125 bp paired-end reads. Approach II: RNA amplicon sequencing. Two sets of YFV-specific primer pairs were designed (Set A: 5 pairs, amplicon length = 2,248 ± 168 nt; Set B: 12 pairs, amplicon length = 1,018 ± 48 nt; S5 Table). PCR products were sequenced by Illumina platform with 2 × 250 bp paired-end reads. Quality control and error correction were implemented according to previous report [28, 29]. The probably low quality regions in sequencing, including 1) Q<30, and 2) the first 10 bps after primers were removed from the high quality sequences, according to a previous study [28]. To minimize sequencing error that affects the accuracy of iSNV calling, we only kept the read-pair that has >100 high quality bases in both ends as clean reads. All reads were deposited in the NCBI SRA database under the accession no. SRP096859.
Sequence alignment and phylogenetic analysis
Consensus sequences were aligned by MUSCLE [30]. Phylogenetic analyses were performed by using RAxML v8.1.6, with the GTR model of nucleotide substitution and γ-distributed rates among sites. Phylogenetic tree was constructed by maximum-likelihood using YFV genome sequences [31]. A NJ tree based on YFV genome sequences was also constructed to show the results were robust (S3 Fig). A total of 1,000 bootstrap replicates were performed. All SNPs were listed in S6 Table. The genome sequences of YF-BJ1, YF-BJ2, YF-BJ3, YF-BJ4, YF-BJ5, YF-FZ2, YF-FZ4, YF-FZ6, and YF-FZ7 were deposited in the NCBI GenBank database under the accession no. MH633684-MH633692.
Calling of iSNVs
To minimize the potential sequencing errors generated by system, we performed the following two steps before we called iSNV, including 1) mapping the clean reads to the reference genome, 2) qualification of the samples. For mapping the clean reads to genome, we use the traditional protocol used widely. First, we mapped the clean reads with pair-ended aligned to the assembled genome from YF-BJ1/7D by using Bowtie2 v2.2.5 [32] with default parameters. SAMtools v1.2 [33] was used to generate ‘mpileup’ files with no limit for the maximum site depth. To find the potential mutation in each site, we do not use the following pipeline in SAMtools. Instead, we developed homemade PERL scripts (available at http://github.com/generality/iSNV-calling/), which were used for iSNV calling to identify all potential mutations by using the mpileup files as input. The depth of bases in each sites were used to measure the mutation rate of iSNV. Then, we selected the samples with more than 3,000 sites with a sequencing depth ≥300× as candidate samples for iSNV calling. Using this protocol, we called iSNV in 15 samples in this study (S1 Table), and obtained the frequencies of each allele in each genome site. Interestingly, we only found the heterogeneous nucleotides with two types in each sites. Thus, we defined the nucleotide with higher frequencies as the major allele, and fewer one as the minor allele in the following iSNV calling.
The iSNV calling was according to the site depth and strand bias with following: 1) remove the ambiguous iSNV and keep the following iSNVs: (1.1) minor allele frequency of ≥5%, a conservative cutoff based on an error rate estimation described before [11, 28]; (1.2) depth of the minor allele of ≥15; and (1.3) strand bias of the minor allele less than tenfold. 2) In our analysis, these two types of nucleotides in each site have contained the nucleotide in the reference genome. Mutated allele frequencies were calculated by the rate of the reads numbers for mutated alleles to the references and total reads. Minor allele and Major allele frequencies were calculated by the majority nucleotides and minor nucleotides in each site respectively. 3) The effect of iSNV to the gene was calculated by the mutation whether caused the amino acid changes.
Phasing analysis of iSNVs
The iSNVs that co-occurred in same viral haplotype(s) within quasispecies was defined as phased iSNVs. 1)We screened the iSNV sites along genome with a window of 250 bp, and then identified all the windows which probably containing a phasing iSNVs. 2) All the sequencing reads aligned to YFV genome region harboring these iSNVs were extracted. 3) The stretches of nearest iSNV were determined by the mutations in the reads aligned to the genome region with the same phasing (supporting reads > = 2). 4) The fractions of reads supporting phased and non-phased neighbor iSNVs were respectively calculated.
Prediction of RNA secondary structures
RNA secondary structures were predicted by using RNAfold program of ViennaRNA Package 2 with default settings [34]. Nucleotide sequences started at the beginning of 3' UTRs of Angola 2016 strain. The length of window for secondary structure prediction was equal to 70 nucleotides. We also extended the additional 200 nucleotides at the end of the sequence, with a step length equal to 50.
Accession numbers
All reads from next generation sequencing were deposited in the NCBI SRA database under the accession no. SRP096859. The genome sequences of YF-BJ1, YF-BJ2, YF-BJ3, YF-BJ4, YF-BJ5, YF-FZ2, YF-FZ4, YF-FZ6, and YF-FZ7 were deposited in the NCBI GenBank database under the accession no. MH633684-MH633692.
Supporting information
Acknowledgments
We thank Prof. Dr. Gong Cheng from Tsinghua University and Prof. Dr. Bo Zhang from Wuhan Institute of Virology, Chinese Academy of Sciences, for helpful discussion.
Data Availability
All reads from next generation sequencing were deposited in the NCBI SRA database under the accession no. SRP096859. The genome sequences of YF-BJ1, YF-BJ2, YF-BJ3, YF-BJ4, YF-BJ5, YF-FZ2, YF-FZ4, YF-FZ6, and YF-FZ7 were deposited in the NCBI GenBank database under the accession no. MH633684-MH633692.
Funding Statement
This work was supported by Grants from China Ministry of Science and Technology Key Research and Development Program [2016YFC1200804 and 2016YFC1200805], Beijing Municipal Science & Technology Commission [Z161100000116049], National Natural Science Foundation of China [91631110 and U1435222], Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support [ZYLX201602NHFPC], Beijing Nova program [Z161100004916101, Z181100006218114], Beijing 215 Project [2015-3-107], China National Grand S&T Special Project [2016ZX10004222-010], and ‘863’ Program [2015AA020108 & 2014AA021501]. WS is supported by the ‘Taishan Scholar’ project of Shandong Province. GW is supported by the President’s International Fellowship Initiative from CAS. JC is supported by CAS Pioneer Hundred Talents Program. GFG is a leading principal investigator of the NSFC Innovative Research Group [81321063]. DL is supported by National Program for Support of Top-notch Young Professionals. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1.Visser LG, Roukens AH. Modelling a way out of yellow fever. Lancet 2016; 388:2847–8. 10.1016/S0140-6736(16)31330-7 [DOI] [PubMed] [Google Scholar]
- 2.Bryant JE, Holmes EC, Barrett AD. Out of Africa: a molecular perspective on the introduction of yellow fever virus into the Americas. PLoS pathogens 2007; 3:e75 10.1371/journal.ppat.0030075 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Mutebi J-P, Rijnbrand RC, Wang H, et al. Genetic relationships and evolution of genotypes of yellow fever virus and other members of the yellow fever virus group within the Flavivirus genus based on the 3′ noncoding region. Journal of virology 2004; 78:9652–65. 10.1128/JVI.78.18.9652-9665.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Stock NK, Laraway H, Faye O, Diallo M, Niedrig M, Sall AA. Biological and phylogenetic characteristics of yellow fever virus lineages from West Africa. Journal of virology 2013; 87:2895–907. 10.1128/JVI.01116-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Vasconcelos PF, Bryant JE, da Rosa APT, Tesh RB, Rodrigues SG, Barrett AD. Genetic divergence and dispersal of yellow fever virus, Brazil. Emerging infectious diseases 2004; 10:1578 10.3201/eid1009.040197 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Kraemer MU, Faria NR, Reiner RC Jr., et al. Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015–16: a modelling study. The Lancet infectious diseases 2016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Chen Z, Liu L, Lv Y, et al. A fatal yellow fever virus infection in China: description and lessons. Emerg Microbes Infect 2016; 5:e69 10.1038/emi.2016.89 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Ling Y, Chen J, Huang Q, et al. Yellow Fever in a Worker Returning to China from Angola, March 2016. Emerging infectious diseases 2016; 22:1317–8. 10.3201/eid2207.160469 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Wang L, Zhou P, Fu X, et al. Yellow fever virus: Increasing imported cases in China. The Journal of infection 2016; 73:377–80. 10.1016/j.jinf.2016.07.003 [DOI] [PubMed] [Google Scholar]
- 10.Sall AA, Faye O, Diallo M, Firth C, Kitchen A, Holmes EC. Yellow fever virus exhibits slower evolutionary dynamics than dengue virus. Journal of virology 2010; 84:765–72. 10.1128/JVI.01738-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Ni M, Chen C, Qian J, et al. Intra-host dynamics of Ebola virus during 2014. Nature microbiology 2016; 1:16151 10.1038/nmicrobiol.2016.151 [DOI] [PubMed] [Google Scholar]
- 12.Proutski V, Gould EA, Holmes EC. Secondary structure of the 3' untranslated region of flaviviruses: similarities and differences. Nucleic acids research 1997; 25:1194–202. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Villordo SM, Carballeda JM, Filomatori CV, Gamarnik AV. RNA Structure Duplications and Flavivirus Host Adaptation. Trends in microbiology 2016; 24:270–83. 10.1016/j.tim.2016.01.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Goz E, Tuller T. Widespread signatures of local mRNA folding structure selection in four Dengue virus serotypes. BMC genomics 2015; 16:S4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Beck A, Tesh RB, Wood TG, Widen SG, Ryman KD, Barrett AD. Comparison of the live attenuated yellow fever vaccine 17D-204 strain to its virulent parental strain Asibi by deep sequencing. The Journal of infectious diseases 2013; 209:334–44. 10.1093/infdis/jit546 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Song R, Guan S, Lee SS, et al. Late or Lack of Vaccination Linked to Importation of Yellow Fever from Angola to China. Emerging infectious diseases 2018; 24:1383. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Monath TP, Barrett AD. Pathogenesis and pathophysiology of yellow fever. Adv Virus Res 2003; 60:343–95. [DOI] [PubMed] [Google Scholar]
- 18.Holmes EC, Dudas G, Rambaut A, Andersen KG. The evolution of Ebola virus: Insights from the 2013–2016 epidemic. Nature 2016; 538:193 10.1038/nature19790 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Bonaldo MC, Gómez MM, dos Santos AA, et al. Genome analysis of yellow fever virus of the ongoing outbreak in Brazil reveals polymorphisms. Memórias do Instituto Oswaldo Cruz 2017; 112:447–51. 10.1590/0074-02760170134 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.McMullan LK, Frace M, Sammons SA, et al. Using next generation sequencing to identify yellow fever virus in Uganda. Virology 2012; 422:1–5. 10.1016/j.virol.2011.08.024 [DOI] [PubMed] [Google Scholar]
- 21.Liang H, Lee M, Jin X. Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine. Cellular & molecular immunology 2016; 13:36–46. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Tabachnick WJ. Climate Change and the Arboviruses: Lessons from the Evolution of the Dengue and Yellow Fever Viruses. Annu Rev Virol 2016; 3:125–45. 10.1146/annurev-virology-110615-035630 [DOI] [PubMed] [Google Scholar]
- 23.Faria NR, Azevedo Rdo S, Kraemer MU, et al. Zika virus in the Americas: Early epidemiological and genetic findings. Science 2016; 352:345–9. 10.1126/science.aaf5036 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Mutebi J-P, Wang H, Li L, Bryant JE, Barrett AD. Phylogenetic and evolutionary relationships among yellow fever virus isolates in Africa. Journal of virology 2001; 75:6999–7008. 10.1128/JVI.75.15.6999-7008.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Allicock OM, Lemey P, Tatem AJ, et al. Phylogeography and population dynamics of dengue viruses in the Americas. Molecular biology and evolution 2012; 29:1533–43. 10.1093/molbev/msr320 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Goz E, Tsalenchuck Y, Benaroya RO, et al. Generation and comparative genomics of synthetic dengue viruses. BMC bioinformatics 2018; 19:140 10.1186/s12859-018-2132-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Woelk CH, Holmes EC. Reduced positive selection in vector-borne RNA viruses. Molecular biology and evolution 2002; 19:2333–6. 10.1093/oxfordjournals.molbev.a004059 [DOI] [PubMed] [Google Scholar]
- 28.Schirmer M, Ijaz UZ, D'Amore R, Hall N, Sloan WT, Quince C. Insight into biases and sequencing errors for amplicon sequencing with the Illumina MiSeq platform. Nucleic acids research 2015; 43:e37 10.1093/nar/gku1341 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Nikolenko SI, Korobeynikov AI, Alekseyev MA. BayesHammer: Bayesian clustering for error correction in single-cell sequencing. BMC Genomics 2013; 14 Suppl 1:S7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic acids research 2004; 32:1792–7. 10.1093/nar/gkh340 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Stamatakis A. RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. Bioinformatics 2006; 22:2688–90. 10.1093/bioinformatics/btl446 [DOI] [PubMed] [Google Scholar]
- 32.Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nature methods 2012; 9:357–9. 10.1038/nmeth.1923 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009; 25:2078–9. 10.1093/bioinformatics/btp352 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Lorenz R, Bernhart SH, Honer Zu Siederdissen C, et al. ViennaRNA Package 2.0. Algorithms Mol Biol 2011; 6:26 10.1186/1748-7188-6-26 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All reads from next generation sequencing were deposited in the NCBI SRA database under the accession no. SRP096859. The genome sequences of YF-BJ1, YF-BJ2, YF-BJ3, YF-BJ4, YF-BJ5, YF-FZ2, YF-FZ4, YF-FZ6, and YF-FZ7 were deposited in the NCBI GenBank database under the accession no. MH633684-MH633692.